Patent classifications
C07K16/104
SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
ANTIBODY MRNA FOR TREATING SARS-CORONAVIRUS-2 DELTA INFECTION AND COMPOSITION INCLUDING SAME
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
ANTIBODY MRNA FOR TREATING SARS-CORONAVIRUS-2 DELTA INFECTION AND COMPOSITION INCLUDING SAME
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Tetrahedral antibodies
This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.
Single domain VHH antibodies against SARS-CoV-2 virus
The invention provides a set of novel Single domain VHH antibodies against SARS-CoV-2 (SEQ ID No 1-6) and their use to detect and neutralize the wild type virus.
Single domain VHH antibodies against SARS-CoV-2 virus
The invention provides a set of novel Single domain VHH antibodies against SARS-CoV-2 (SEQ ID No 1-6) and their use to detect and neutralize the wild type virus.